ODYY Odyssey Group International

Filed: 24 Sep 21, 4:01pm







Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):

September 22, 2021



(Exact name of small business issuer as specified in its charter)



(State or other jurisdiction of incorporation)

(Commission File Number)(IRS Employer ID No.)


2372 Morse Avenue

Irvine, CA 92614

(Address of Principal Executive Offices)


(619) 832-2900

(Issuer’s Telephone Number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Securities registered pursuant to Section 12(b) of the Act:


Title of each classTrading Symbol(s)Name of each exchange on which registered
Not ApplicableNot ApplicableNot Applicable


Securities registered pursuant to Section 12(g) of the Act:


Title of each ClassTrading SymbolName of Each Exchange on Which Registered
Common Stock ($0.001 par value)ODYYOTC



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 8.01Other Material Event


On September 22, 2021, Odyssey Group International, Inc. (the “Odyssey”) announced successful completion of its clinical trial site initiation visit and the start of subject screening and enrollment. The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally. Odyssey’s Phase 1 clinical trial status can be viewed at


Item 7.01Regulation FD Disclosure


Attached is a copy of a press release being issued by the Company relating to the above-referenced matter, a copy of which is attached as Exhibit 99.1 and is hereby incorporated.


Item 9.01.Financial Statements and Exhibits.


(c) Exhibits.


99.1Press Release



























Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: September 24, 2021Odyssey Group International, Inc.
 By: /s/ J. Michael Redmond
  Chief Executive Officer